DMD Noab BioDiscoveries - Shaping Drug Discovery

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on March 15, 2006; DOI: 10.1124/dmd.105.008631


0090-9556/06/3406-976-983$20.00
DMD 34:976-983, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.105.008631v1
34/6/976    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhou, D.
Right arrow Articles by Zamora, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhou, D.
Right arrow Articles by Zamora, I.

COMPARISON OF METHODS FOR THE PREDICTION OF THE METABOLIC SITES FOR CYP3A4-MEDIATED METABOLIC REACTIONS

Diansong Zhou, Lovisa Afzelius, Scott W. Grimm, Tommy B. Andersson, Randy J. Zauhar, and Ismael Zamora

Department of Drug Metabolism and Pharmacokinetics, AstraZeneca Pharmaceuticals, Wilmington, Delaware (D.Z., S.W.G.); Department of Chemistry & Biochemistry, the University of Sciences in Philadelphia, Philadelphia, Pennsylvania (D.Z., R.J.Z.); Department of Drug Metabolism and Pharmacokinetics & Bioanalytical Chemistry, AstraZeneca R&D, Molndal, Sweden (L.A., T.B.A.); Division of Molecular Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden (T.B.A.); Lead Molecular Design, Barcelona, Spain (I.Z.); and GRIB-IMIM, Barcelona, Spain (I.Z.)

Predictions of the metabolic sites for new chemical entities, synthesized or only virtual, are important in the early phase of drug discovery to guide chemistry efforts in the synthesis of new compounds with reduced metabolic liability. This information can now be obtained from in silico predictions, and therefore, a thorough and unbiased evaluation of the computational techniques available is needed. Several computational methods to predict the metabolic hot spots are emerging. In this study, metabolite identification using MetaSite and a docking methodology, GLUE, were compared. Moreover, the published CYP3A4 crystal structure and computed CYP3A4 homology models were compared for their usefulness in predicting metabolic sites. A total of 227 known CYP3A4 substrates reported to have one or more metabolites adding up to 325 metabolic pathways were analyzed. Distance-based fingerprints and four-point pharmacophore derived from GRID molecular interaction fields were used to characterize the substrate and protein in MetaSite and the docking methodology, respectively. The CYP3A4 crystal structure and homology model with the reactivity factor enabled achieved a similar prediction success (78%) using the MetaSite method. The docking method had a relatively lower prediction success (~57% for the homology model), although it still may provide useful insights for interactions between ligand and protein, especially for uncommon reactions. The MetaSite methodology is automated, rapid, and has relatively accurate predictions compared with the docking methodology used in this study.


Address correspondence to: Diansong Zhou, Department of Drug Metabolism and Pharmacokinetics, AstraZeneca Pharmaceuticals, 1800 Concord Pike, Wilmington, DE 19810. E-mail: diansong.zhou{at}AstraZeneca.com




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
S. Goel, M. Cohen, S. N. Comezoglu, L. Perrin, F. Andre, D. Jayabalan, L. Iacono, A. Comprelli, V. T. Ly, D. Zhang, et al.
The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development
Clin. Cancer Res., May 1, 2008; 14(9): 2701 - 2709.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.